EP3914247
Notkun á mígalóstat við að draga úr áhættunni á heila- og æða-atburði í sjúklingum með Fabry-sjúkdóm
Status:
EP einkaleyfi í gildi á ÍslandiEP appl. date:
22.1.2020EP published:
13.11.2024EP application number:
20708283.5
EP translation filed:
20.1.2025Grant published:
15.2.2025EPO information:
European Patent Register
Max expiry date:
21.1.2040Expiry date:
21.1.2027Next due date:
31.1.2027
Title in English:
USE OF MIGALOSTAT IN REDUCING THE RISK OF CEREBROVASCULAR EVENT IN PATIENTS WITH FABRY DISEASELanguage of the patent:
English
Timeline
Today
22.1.2020EP application
13.11.2024EP Publication
20.1.2025Translation submitted
15.2.2025Registration published
21.1.2027Expires
Owner
Name:
Amicus Therapeutics, Inc.Address:
3675 Market Street, Philadelphia, PA 19104, US
Inventor
Name:
SKUBAN, NinaAddress:
Cranbury, New Jersey 08512, US
Name:
LAGAST, HjalmarAddress:
Cranbury, New Jersey 08512, US
Agent
Name:
Árnason Faktor ehf.Address:
Guðríðarstíg 2-4, 113, Reykjavík,
Priority
Number:
201962795524 PDate:
22.1.2019Country:
US
Classification
Categories:
A61K 31/445, A61P 9/00, A61P 25/00
Annual fees
Number
Paid
Expires
Payer
Number: 6
Paid: 13.12.2024
Expires: 21.1.2026
Payer: Árnason Faktor ehf.
Number: 7
Paid: 13.1.2026
Expires: 21.1.2027
Payer: Árnason Faktor ehf.